Korea Pharma Co Ltd

Korea Pharma Co Ltd exhibits a capital structure with a debt-to-equity ratio of 0.57, indicating moderate leverage relative to its equity base. The company holds cash and equivalents of KRW 6,151,509,350, but its long-term debt of KRW 38,937,353,380 exceeds this amount, resulting in a net cash position that is negative after subtracting total debt. The current ratio of 1.14 suggests limited short-term liquidity, as the company's current assets only slightly exceed its current liabilities. Profitability metrics show significant underperformance relative to industry norms. The company reported a net loss of KRW 2,640,407,220 and an operating loss of KRW 1,081,610,370, with a return on equity of -3.84% and a return on assets of -2.08%. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its asset base, which is a concern in a capital-intensive industry like pharmaceuticals. The company's revenue is concentrated in a few product categories, including antidepressants, blood circulation agents, and antidementia drugs, with no disclosed geographic diversification in the input data. This lack of geographic segmentation data limits visibility into potential regional exposure or concentration risk. Growth trajectory appears negative in the near term. The company reported a net loss in the latest period, and no positive revenue growth is indicated in the input data. The absence of a forward-looking outlook in the input data prevents a more detailed assessment of future revenue expectations. Risk factors include medium liquidity risk, as the company's cash and equivalents are insufficient to cover its long-term debt obligations. The risk of dilution is assessed as low, but the company's negative free cash flow of KRW -1,376,686,120 and capital expenditure of KRW -1,332,046,850 suggest ongoing financial pressure that could necessitate future financing. Recent events include the latest financial filing, which discloses the company's operating and net losses, as well as its capital structure. No additional events, such as earnings calls or regulatory filings, are provided in the input data.